Market Overview

Alucent Biomedical Completes Formation of Executive Leadership Team


Company Developing a Potential Breakthrough Combination
Drug-Device Therapy for Vascular Disease

- a privately held biotechnology company founded to
transform the way vascular disease is treated, today announced the
appointment of six new members to its executive
leadership team
. The new members bring decades of experience in the
areas of biotechnology, cardiovascular disease and product development
to the company.

The additions to the executive leadership team include:

  • Katalin
    Kauser, M.D., Ph.D, D.Sc.
    , vice president of biology,
    joins Alucent Biomedical after 20 years of experience in the
    biotechnology and pharmaceutical industry with such firms as Global
    Blood Therapeutics, Boehringer Ingelheim, Actelion, and Bayer,
    specializing in cardiovascular biology, pharmacology, and drug
  • Bruce
    , vice president of regulatory affairs, has
    more than 30 years of experience leading global regulatory and
    clinical affairs for start-up and large medical device companies. He
    most recently served as vice president of global regulatory affairs
    for Allergan, where he led worldwide regulatory affairs for the
    company's entire $3 billion medical device franchise.
  • Julie
    , vice president of clinical affairs, has more than 20
    years of experience in the interventional cardiovascular field
    conducting clinical trials on behalf of many start-up medical device
    companies, developing cutting-edge cardiovascular products and
    performing complex coronary, vascular and structural interventions.
  • Scott
    Mayfield, CPA
    , vice president of finance and
    administration, brings more than 20 years of experience managing
    finance, accounting and human resources for CRBard and Boston
    Scientific and for growing life science companies, such as Catheter
    Innovations, InnerDyne, Perseon, and Catheter Technology Corp., funded
    by venture capital, private equity and angel investors.
  • Jane
    Ren, Ph.D.
    , vice president of research & development
    and chief technology officer, joins Alucent with 20 years of
    experience developing interventional medical devices and drug delivery
    technologies. Her previous positions included VP at Boston Scientific,
    and Chief Technology Officer at CeloNova BioSciences. During her
    tenure at these companies, she led cross-functional teams for both
    interventional oncology and interventional cardiology platforms,
    throughout all phases of development and commercialization.
  • Kevin
    Warner, Ph.D.
    , vice president of pharmaceutical
    development, joins Alucent Biomedical with 15 years of pharmaceutical
    development experience. He was most recently at Allergan, Inc., where
    he held roles of increasing responsibility in pharmaceutical product
    development, including serving most recently as director of small
    molecule development.

"The in-depth expertise our executive team brings to the table will
accelerate Alucent's progress towards the goal of bringing Natural
Vascular Scaffolding™
treatment to patients suffering from vascular
disease," said Myles Greenberg, M.D., president and chief executive
officer of Alucent Biomedical. "I am excited to be working with such an
accomplished group of executives to advance the company's groundbreaking

About Alucent Biomedical, Inc.

Alucent Biomedical, Inc. is a privately held biotechnology company
headquartered in Salt Lake City, Utah and is the first company to bring
a novel, locally delivered biotechnology treatment to a market
traditionally dominated by medical device solutions. Alucent was founded
by Avera
to develop and market Natural Vascular Scaffolding (NVS). NVS
is a first-of-a-kind combination drug-device therapy designed to assist
the body in naturally opening and maintaining arterial patency.

View Comments and Join the Discussion!